253 related articles for article (PubMed ID: 29346270)
21. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
Oliveira M; Mesplède T; Moïsi D; Ibanescu RI; Brenner B; Wainberg MA
AIDS; 2015 Nov; 29(17):2255-60. PubMed ID: 26372484
[TBL] [Abstract][Full Text] [Related]
22. The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
Xiao MA; Cleyle J; Yoo S; Forrest M; Krullaars Z; Pham HT; Mesplède T
Antimicrob Agents Chemother; 2023 May; 67(5):e0138622. PubMed ID: 37071019
[TBL] [Abstract][Full Text] [Related]
23. The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro.
Saladini F; Giannini A; Boccuto A; Tiezzi D; Vicenti I; Zazzi M
AIDS; 2017 Oct; 31(16):2307-2309. PubMed ID: 28832412
[TBL] [Abstract][Full Text] [Related]
24. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.
Wares M; Mesplède T; Quashie PK; Osman N; Han Y; Wainberg MA
Retrovirology; 2014 Jan; 11():7. PubMed ID: 24433497
[TBL] [Abstract][Full Text] [Related]
25. Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients.
Sayan M; Gündüz A; Ersöz G; İnan A; Deveci A; Özgür G; Sargın F; Karagöz G; İnci A; İnan D; Ülçay A; Karaoğlan I; Kaya S; Kutlu SS; Süer K; Çağatay A; Akalın H
HIV Clin Trials; 2016 May; 17(3):109-13. PubMed ID: 27125365
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
Varghese V; Liu TF; Rhee SY; Libiran P; Trevino C; Fessel WJ; Shafer RW
AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1323-6. PubMed ID: 20961278
[TBL] [Abstract][Full Text] [Related]
27. Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
Mikasi SG; Isaacs D; Chitongo R; Ikomey GM; Jacobs GB; Cloete R
BMC Infect Dis; 2021 Apr; 21(1):379. PubMed ID: 33892628
[TBL] [Abstract][Full Text] [Related]
28. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
Nguyen HL; Ruxrungtham K; Delaugerre C
Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
[TBL] [Abstract][Full Text] [Related]
29. [Resistance profile and genetic barrier of dolutegravir].
Llibre JM; Clotet B
Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():20-5. PubMed ID: 25858608
[TBL] [Abstract][Full Text] [Related]
30. Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study.
Uno S; Gatanaga H; Hayashida T; Imahashi M; Minami R; Koga M; Samukawa S; Watanabe D; Fujii T; Tateyama M; Nakamura H; Matsushita S; Yoshino Y; Endo T; Horiba M; Taniguchi T; Moro H; Igari H; Yoshida S; Teshima T; Nakajima H; Nishizawa M; Yokomaku Y; Iwatani Y; Hachiya A; Kato S; Hasegawa N; Yoshimura K; Sugiura W; Kikuchi T
J Antimicrob Chemother; 2023 Dec; 78(12):2859-2868. PubMed ID: 37856677
[TBL] [Abstract][Full Text] [Related]
31. E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection.
Ambrosioni J; Rico JÁF; Nicolás D; Mosquera MM; de Lazzari E; Marcos MÁ; García F; Miró JM;
AIDS; 2019 Aug; 33(10):1613-1617. PubMed ID: 31090546
[TBL] [Abstract][Full Text] [Related]
32. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
[TBL] [Abstract][Full Text] [Related]
33. Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.
Meixenberger K; Yousef KP; Smith MR; Somogyi S; Fiedler S; Bartmeyer B; Hamouda O; Bannert N; von Kleist M; Kücherer C
Virol J; 2017 Nov; 14(1):223. PubMed ID: 29137637
[TBL] [Abstract][Full Text] [Related]
34. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Boeri E; Spagnuolo V; Cossarini F; Castagna A; Lazzarin A; Clementi M
J Infect Dis; 2011 Dec; 204(11):1811-5. PubMed ID: 21984737
[TBL] [Abstract][Full Text] [Related]
35. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea.
Kim JY; Kim EJ; Choi JY; Kwon OK; Kim GJ; Choi SY; Kim SS
Clin Microbiol Infect; 2011 Aug; 17(8):1155-9. PubMed ID: 20946407
[TBL] [Abstract][Full Text] [Related]
36. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.
Rhee SY; Liu TF; Kiuchi M; Zioni R; Gifford RJ; Holmes SP; Shafer RW
Retrovirology; 2008 Aug; 5():74. PubMed ID: 18687142
[TBL] [Abstract][Full Text] [Related]
37. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
Quashie PK; Mesplède T; Han YS; Oliveira M; Singhroy DN; Fujiwara T; Underwood MR; Wainberg MA
J Virol; 2012 Mar; 86(5):2696-705. PubMed ID: 22205735
[TBL] [Abstract][Full Text] [Related]
39. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
Karade S; Sen S; Sashindran VK
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
[TBL] [Abstract][Full Text] [Related]
40. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
